TrialNature communications2024

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

Jonathan I Silverberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.